European Journal of Clinical Pharmacology

, Volume 70, Issue 7, pp 775–789

Drug interactions and protease inhibitors used in the treatment of hepatitis C: How to manage?

  • Sarah Talavera Pons
  • Geraldine Lamblin
  • Anne Boyer
  • Valérie Sautou
  • Armand Abergel
Review Article

Abstract

Purpose

The first-generation protease inhibitors (PI) boceprevir and telaprevir combined with pegylated interferon have revolutionized the treatment of type-1 hepatitis C by increasing the rates of sustained virologic response. However, they induce drug interactions, and their clinical relevance is difficult to predict. This review compiles available data on drug–drug interactions (DDI) based on their pharmacokinetic and pharmacodynamic properties with the aim of assisting clinicians in managing DDI

Methods

PubMed, drug interaction databases and hepatology and infectious disease conference abstracts were systematically searched using the key search terms “interaction”, “hepatitis C”, “telaprevir” and “boceprevir”. All known interactions were compiled and reclassified according to their pharmacokinetic and pharmacodynamic mechanisms. The state of knowledge of interaction mechanisms are reported and a therapeutic approach is proposed.

Results

Boceprevir and telaprevir are both substrates and potent inhibitors of cytochrome P450 3A4 and the drug transporter P-glycoprotein. They induce overdosage but can sometimes decrease the effect of other drugs by inducing other cytochromes. Overdosage or low dosage mainly affects drugs with a narrow therapeutic range, such as immunosuppressants or antiretrovirals. The distribution and elimination of PI are unaffected by interactions. In terms of pharmacodynamic interactions, PI can trigger drug-induced QT interval prolongation, which means that clinicians should manage such risk factors as potassium/magnesium levels or avoid other QT-prolonging drugs.

Conclusions

Management of hepatitis C therapy is complex. The key to interpreting DDI data is a solid understanding of the pharmacokinetic and pharmacodynamic profiles of the drugs involved. Their ability to inhibit cytochrome P450 3A4 and prolong the QT interval can have significant clinical consequences. This review provides a practical guide to the safe and effective management of therapy with boceprevir and telaprevir.

Keywords

Interaction Telaprevir Boceprevir Management 

References

  1. 1.
    McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH et al (2010) Telaprevir for previously treated chronic HCV infection. N Engl J Med 362(14):1292–1303PubMedCrossRefGoogle Scholar
  2. 2.
    Sherman KE, Flamm SL, Afdhal NH et al (2011) Response-guided Telaprevir combination treatment for Hepatitis C Virus infection. N Engl J Med 365(11):1014–1024PubMedCrossRefGoogle Scholar
  3. 3.
    Poordad F, McCone J, Bacon BR et al (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364(13):1195–1206PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Zeuzem S, Andreone P, Pol S et al (2011) Telaprevir for retreatment of HCV infection. N Engl J Med 364(25):2417–2428PubMedCrossRefGoogle Scholar
  5. 5.
    Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB (2011) An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54(4):1433–1444PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Merck Canada Inc (2013) Victrelis (Boceprevir) product monograph. Merck Canada Inc, KirklandGoogle Scholar
  7. 7.
    Vertex Pharmaceuticals Inc. (2013) Incivek (Telaprevir) product monograph. Vertex Pharmaceuticals Inc., LavalGoogle Scholar
  8. 8.
    Kasserra C, Hughes EA, Treitel M (2011) Clinical pharmacology of Boceprevir: metabolism, excretion, and drug-drug interactions (abstract 118). In: Abstract book of the 18th Conference on Retroviruses and Opportunistic Infections. BostonGoogle Scholar
  9. 9.
    Levêque D, Lemachatti J, Nivoix Y et al (2010) Mécanismes des interactions médicamenteuses d’origine pharmacocinétique. Rev Med Intern 31(2):170–179CrossRefGoogle Scholar
  10. 10.
    Van Heeswijk R, Boogaerts G, De Paepe E. (2011) The effect of different types of food on the bioavailability of the investigational HCV protease inhibitor Telaprevir (abstract PK_19). In: Abstract book of the 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy. Reviews in Antiviral Therapy & Infectious Diseases (6):21. CambridgeGoogle Scholar
  11. 11.
    Benet L, Hoener B (2002) Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71:115–121PubMedCrossRefGoogle Scholar
  12. 12.
    Lin JH, Yamazaki M (2003) Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 42(1):59–98PubMedCrossRefGoogle Scholar
  13. 13.
    Ghosal A, Yuan Y, Tong W, Su A-D et al (2011) Characterization of human liver enzymes involved in the biotransformation of Boceprevir, a Hepatitis C Virus protease inhibitor. Drug Metab Dispos 39(3):510–521PubMedCrossRefGoogle Scholar
  14. 14.
    Garg V, Chandorkar G, Farmer HF, Smith F, Alves K, van Heeswijk RPG (2012) Effect of Telaprevir on the pharmacokinetics of midazolam and digoxin. J Clin Pharmacol 52(10):1566–1573PubMedCrossRefGoogle Scholar
  15. 15.
    Jumes P, Feng H-P, Xuan F, et al (2012) Pharmacokinetic interaction between the HCV protease inhibitor Boceprevir and Digoxin in healthy adult volunteers (abstract PK_05). In: 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy. Reviews in Antiviral Therapy & Infectious Diseases (7):8 CambridgeGoogle Scholar
  16. 16.
    Burger D, Back D, Buggisch P et al (2013) Clinical management of drug–drug interactions in HCV therapy: Challenges and solutions. J Hepatol 58(4):792–80020PubMedCrossRefGoogle Scholar
  17. 17.
    Kis O, Robillard K, Chan G, Bendayan R (2010) The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci 31:22–25PubMedCrossRefGoogle Scholar
  18. 18.
    Henshaw J, Adiwijaya B, Adda N, et al (2012) The pharmacokinetics of Telaprevir and selected ART medications in HCV/HIV co-infected patients (abstract PK_08). In: 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy Reviews in Antiviral Therapy & Infectious Diseases (7):11. CambridgeGoogle Scholar
  19. 19.
    Van Heeswijk R, Vandevoorde A, Boogaerts G, et al (2011) Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers (abstract 119]. In: 18th Conference on Retroviruses and Opportunistic Infections. BostonGoogle Scholar
  20. 20.
    Neuvonen P, Niemi M, Backman J (2006) Drug interactions with lipid lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80:565–581PubMedCrossRefGoogle Scholar
  21. 21.
    Hulskotte EG1, Feng HP, Xuan F, Gupta S, van Zutven MG, O'Mara E, Wagner JA, Butterton JR (2013) Pharmacokinetic evaluation of the interaction between the HCV protease inhibitor Boceprevir and the HMG-CoA reductase inhibitors Atorvastatin and Pravastatin. Antimicrob Agents Chemother 57(6):2582–8 Google Scholar
  22. 22.
    Kunze A, Huwyler J, Camenisch G et al (2012) Interaction of the antiviral drug Telaprevir with renal and hepatic drug transporters. Biochem Pharmacol 84:1096–1102PubMedCrossRefGoogle Scholar
  23. 23.
    Huang S-M, Temple R, Throckmorton DC, Lesko LJ (2007) Druginteraction studies: Study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 81(2):298–304PubMedCrossRefGoogle Scholar
  24. 24.
    Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X (2011) Effect of Telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 54(1):20–27PubMedCrossRefGoogle Scholar
  25. 25.
    Hulskotte E1, Gupta S, Xuan F, van Zutven M, O'Mara E, Feng HP, Wagner J, Butterton J (2012) Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 56(5):1622–30Google Scholar
  26. 26.
    Kiser JJ, Burton JR, Anderson PL, Everson GT (2012) Review and management of drug interactions with Boceprevir and Telaprevir. Hepatology 55(5):162–168CrossRefGoogle Scholar
  27. 27.
    Wilby KJ, Greanya ER, Ford JAE, Yoshida E, Partovi N (2012) A review of drug interactions with Boceprevir and Telaprevir: implications for HIV and Transplant patients. Ann Hepatol 11(2):179–185PubMedGoogle Scholar
  28. 28.
    Saxena V, Terrault N (2012) Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies. Curr Opin Organ Transplant 17(3):216–224PubMedCrossRefGoogle Scholar
  29. 29.
    Coilly A, Furlan V, Roche B, Barau C et al (2012) Practical management of Boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. Antimicrob Agents Chemother 56(11):5728–5734PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    O’Leary JG, McKenna GJ, Klintmalm GB, Davis GL (2013) Effect of Telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients. Liver Transpl 19(4):463–465PubMedCrossRefGoogle Scholar
  31. 31.
    Vourvahis M, Plotka A, Kantaridis C, et al (2013) The effect of Boceprevir and Telaprevir on the pharmacokinetics of Maraviroc: an open-label, fixed-sequence study in healthy volunteers [O_17]. In: 14th International Workshop on Clinical Pharmacology of HIV Therapy. Reviews in Antiviral Therapy & Infectious Diseases  (3):20 AmsterdamGoogle Scholar
  32. 32.
    Van Heeswijk RP, Beumont M, Kauffman RS, Garg V (2013) Review of drug interactions with Telaprevir and antiretrovirals. Antivir Ther 18(4):553–560PubMedCrossRefGoogle Scholar
  33. 33.
    De Kanter CTMM, Blonk MI, Colbers APH, Schouwenberg BJJW, Burger DM (2013) Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor Boceprevir and the HIV integrase inhibitor raltegravir. Clin Infect Dis 56(2):300–306PubMedCrossRefGoogle Scholar
  34. 34.
    Henshaw J, Adiwijaya B, Adda N, et al. (2012) The pharmacokinetics of Telaprevir and selected ART medications in HCV/HIV co-infected patients [abstract PK_08]. In: 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy. Reviews in Antiviral Therapy & Infectious Diseases (7):11 CambridgeGoogle Scholar
  35. 35.
    Moreno A, Quereda C, Montes M et al (2012) Safe coadministration of raltegravir-based HAART in HIV infected patients with HCV-cirrhosis receiving triple therapy with Telaprevir or Boceprevir. J Acq Immune Def Syndr 61(3):e47–e49CrossRefGoogle Scholar
  36. 36.
    Van Heeswijk RPG, Garg V, Boogaerts G, et al (2011) The pharmacokinetic interaction between Telaprevir and raltegravir in healthy volunteers (abstract A1-1738a). In: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. ChicagoGoogle Scholar
  37. 37.
    Seden K, Back D (2011) Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. Curr Opin HIV AIDS 6(6):514–526PubMedCrossRefGoogle Scholar
  38. 38.
    Piroth L (2011) Direct-acting antivirals for hepatitis C virus infections in patients co-infected with human immunodeficiency virus. Clin Res Hepatol Gastroenterol 35[Suppl 2]:S75–S83PubMedCrossRefGoogle Scholar
  39. 39.
    Garg V, Chandorkar G, Yang Y, Adda N et al (2013) The effect of CYP3A inhibitors and inducers on the pharmacokinetics of Telaprevir in healthy volunteers. Br J Clin Pharmacol 75(2):431–439PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Rangnekar AS, Fontana RJ (2012) Managing drug-drug interactions with Boceprevir and Telaprevir. Clin Liv Dis 1(2):36–40CrossRefGoogle Scholar
  41. 41.
    Van Heeswijk RPG, Vandevoorde A, Boogaerts G et al (2011) Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers (abstract 119). In: 18th Conference on Retroviruses and Opportunistic Infections. BostonGoogle Scholar
  42. 42.
    Bidstrup TB, Stilling N, Damkier P, Scharling B, Thomsen MS, Brøsen K (2004) Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur J Clin Pharmacol 60(2):109–114PubMedCrossRefGoogle Scholar
  43. 43.
    Zheng HX, Huang Y, Frassetto LA, Benet LZ (2009) Elucidating rifampin’s inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther 85(1):78–85PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.
    Van Giersbergen PLM, Treiber A, Schneiter R, Dietrich H, Dingemanse J (2007) Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin Pharmacol Ther 81(3):414–419PubMedCrossRefGoogle Scholar
  45. 45.
    Garg V, van Heeswijk R, Yang Y, Kauffman R, Smith F, Adda N (2012) The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor Telaprevir. J Clin Pharmacol 52(10):157–1583Google Scholar
  46. 46.
    Gatti DC, Cha A (2012) Apparent interaction between Telaprevir and warfarin in a patient with chronic hepatitis C viral infection. Am J Health Syst Pharm 69(23):2062–2065PubMedCrossRefGoogle Scholar
  47. 47.
    Roden D (2004) Drug-induced prolongation of the QT interval. N Engl J Med 350:1013–1022PubMedCrossRefGoogle Scholar
  48. 48.
    University of Arizona Center for Education and Research on Therapeutics. Available at: www.qtdrugs.org
  49. 49.
    Nolan M (2012) EMA approved new drugs: Telaprevir and Boceprevir Direct acting antivirals rewrite guidelines for the treatment of hepatitis. Eur J Hosp Pharm 19:299–300Google Scholar
  50. 50.
    Al-Khatib SM, Allen LaPointe NM, Kramer JM, Califf RM (2003) What clinicians should know about the qt interval—correction. JAMA 290(10):1318Google Scholar
  51. 51.
    Hulskotte EGJ, Gupta S., Xuan F. et al (2011) Coadministration of the HCV protease inhibitor Boceprevir has no clinically meaningful effect on the pharmacokinetics of the selective serotonin reuptake inhibitor escitalopram in healthy volunteers. (Abstract 121) published in Global Antiviral Journal, Volume 7, Suppl. 1: HEP DART 2011: 121 Koloa, HawaiiGoogle Scholar
  52. 52.
    Hulskotte EGJ, Feng H-P, Xuan F et al (2013) Pharmacokinetic evaluation of the interaction betweenthe HCV protease inhibitor Boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin. Antimicrob Agents Chemother 57:2582–2588PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.
    Hulskotte EGJ, Gupta G, Xuan F, et al (2012) Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. (Abstract 121) published in Global Antiviral Journal, Volume 7, Suppl. 1: HEP DART 2011: 110Google Scholar
  54. 54.
    Hulskotte EGJ, Feng H-P, Xuan F, et al (2013) Pharmacokinetic interactions between the HCV protease inhibitor Boceprevir and sirolimus in healthy subjects (abstract 463). In: 48th Annual Meeting of the European Association for the Study of the Liver (EASL. J. Hepatology 2013 (58), Supplement 1 : S1-S632)Google Scholar
  55. 55.
    Garraffo R, Lavrut T, Poisot-Martin I, et al (2013) Pharmacokinetic interactions between Boceprevir and atazanavir/ritonavir or raltegravir in HIV/HCV coinfected patients (abstract O_15). In: 14th International Workshop on Clinical Pharmacology of HIV Therapy. Reviews in Antiviral Therapy & Infectious Diseases (3):18. AmsterdamGoogle Scholar
  56. 56.
    Hammond K, Wolfe P, Burton J et al (2013) Pharmacokinetic interaction between Boceprevir and etravirine in HIV/HCV seronegative volunteers. J Acq Immune Def Syndr 62(1):67–73CrossRefGoogle Scholar
  57. 57.
    Hulskotte EG1, Feng HP, Xuan F, et al (2013) Absence of a significant pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis 56(5):718–26Google Scholar
  58. 58.
    Rhee E, Feng H-P, Xuan F et al (2013) Absence of a significant pharmacokinetic interaction between the hepatitis C virus protease inhibitor Boceprevir and HIV-1 NNRTI rilpivirine (abstract 537). In: 20th Conference on Retroviruses and Opportunistic Infections. AtlantaGoogle Scholar
  59. 59.
    Vourvahis M, Plotka A, Kantaridis C et al. (2013) The effect of Boceprevir and Telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers (O_17). In: 14th International Workshop on Clinical Pharmacology of HIV Therapy. Published in Reviews in Antiviral Therapy & Infectious Diseases (3):20. AmsterdamGoogle Scholar
  60. 60.
    Johnson M, Borland J, Chen S et al (2013) The effect of Boceprevir and Telaprevir on dolutegravir pharmacokinetics, in healthy adult subjects [abstract O_16]. 14th International Workshop on Clinical Pharmacology of HIV Therapy, April 22-24, published in Reviews in Antiviral Therapy & Infectious Diseases (3):19. AmsterdamGoogle Scholar
  61. 61.
    Lin WH, Feng H-P, Chatterjee M et al (2012) Pharmacokinetic interaction between the hepatitis C virus protease inhibitor Boceprevir and ethinylestradiol/norethindrone (abstract 1901). In: 63rd Annual Meeting of the American Association for the Study of Liver Diseases. Hepatology 56(4):1078A. BostonGoogle Scholar
  62. 62.
    Jumes P, Feng H-P, Chatterjee M et al (2012) Pharmacokinetic interaction between the hepatitis Cvirus protease inhibitor Boceprevir and prednisone in healthy volunteers (abstract 1896). In: 63rdAnnual Meeting of the American Association for the Study of Liver Diseases. Hepatology 56(4):1076A. BostonGoogle Scholar
  63. 63.
    de Kanter CT1, Colbers AP, Blonk MI, Verweij-van Wissen CP, Schouwenberg BJ, Drenth JP, Burger DM. Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole. J Antimicrob Chemother. 2013 Jun;68(6):1415–22Google Scholar
  64. 64.
    Hulskotte EGJ, Feng H-P, Bruce RD et al (2012) Pharmacokinetic interaction between HCV protease inhibitor Boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy (abstract PK_09). 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy. Reviews in Antiviral Therapy & Infectious Diseases 2012 (7):12. CambridgeGoogle Scholar
  65. 65.
    Poordad F, Lawitz E, Gordon S, et al (2011) Concomitant medication use in patients with hepatitis C genotype 1 treated with Boceprevir combination therapy ([poster 937). In: 62nd Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco Hepatology 54(4):799A. San FranciscoGoogle Scholar
  66. 66.
    van Heeswijk R, Boogaerts G, De Paepe E, van Solingen-Ristea R, Garg V, Beumont M. (2010) The pharmacokinetic (PK) interaction between escitalopram and the investigational HCV protease inhibitor Telaprevir. Presented at the 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy. Reviews in Antiviral Threapy and Infectious disease 5:12Google Scholar
  67. 67.
    Luo X, van Heeswijk R, Alves K, Garg V (2011) The effect of Telaprevir on the pharmacokinetics of Alprazolam and Zolpidem in healthy volunteers (abstract PK_11). In: 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy. Reviews in Antiviral Threapy and Infectious Diseases 6:13. CambridgeGoogle Scholar
  68. 68.
    Lee JE, Van Heeswijk RPG, Alves K et al (2011) Effect of the hepatitis C virus protease inhibitor Telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob Agents Chemother 55(10):4569–4574PubMedCentralPubMedCrossRefGoogle Scholar
  69. 69.
    Garg V, Chandorkar G, Farmer HF, Smith F, Alves K, van Heeswijk RP (2012) Effect of Telaprevir on the pharmacokinetics of midazolam and digoxin. J Clin Pharmacol 52(10):1566–1573PubMedCrossRefGoogle Scholar
  70. 70.
    Van Heeswijk RPG, Verboven P, Vandevoorde A et al (2013) Pharmacokinetic interaction between Telaprevir and methadone. Antimicrob Agents Chemother 57:2304–2309PubMedCentralPubMedCrossRefGoogle Scholar
  71. 71.
    Van Heeswijk R, Vandevoorde A, Verboven P et al (2011) The pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor Telaprevir. J Hepatol 54:S491–S49.2CrossRefGoogle Scholar
  72. 72.
    Luo X, Trevejo J, Van Heeswijk RPG et al (2012) Effect of Telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy. Antimicrob Agents Chemother 56(7):3641–3647PubMedCentralPubMedCrossRefGoogle Scholar
  73. 73.
    Kraft K, Martin D, Streepey D et al (2012) Telaprevir interferes with levothyroxine treatment of hypothyroidism (abstract 1845). In: 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Hepatology 56(4):1053A. BostonGoogle Scholar
  74. 74.
    Gatti DC, Cha A (2012) Apparent interaction between Telaprevir and warfarin in a patient with chronic hepatitis C viral infection. Am J Health Syst Pharm 69(23):2062–2065PubMedCrossRefGoogle Scholar
  75. 75.
    Hammond KP, Jimmerson L, MacBrayne CE et al (2013) Increased plasma and intracellular ribavirin concentrations associated with Telaprevir use. (Abstract PP_2) In: 14th International Workshop on Clinical Pharmacology of HIV Therapy. Reviews in Antiviral Therapy & Infectious Diseases 3:26. AmsterdamGoogle Scholar
  76. 76.
    Garg V, Luo X, McNair L et al (2011) Low-dose ritonavir and the pharmacokinetics of the investigational HCV protease inhibitor Telaprevir in healthy volunteers (abstract 629). In: 18th Conference on Retroviruses and Opportunistic Infections. BostonGoogle Scholar
  77. 77.
    Van Heeswijk R, Gysen V, Googaerts G, et al (2008) The pharmacokinetic interaction between tenofovirdisoproxilfumarate and the investigational HCV protease inhibitor Telaprevir (abstract A-966). In: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy Washington DCGoogle Scholar
  78. 78.
    Custodio JM, Guo S, Lawson E et al. (2013) Lack of clinically relevant drug interactions between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir disoproxilfumarate and Telaprevir. (Abstract A-1576) In 53th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), DenverGoogle Scholar
  79. 79.
    Vourvahis M, Plotka A, Kantaridis C et al (2013) The effect of Boceprevir and Telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers (O_17). In: 14th International Workshop on Clinical Pharmacology of HIV Therapy. Reviews in Antiviral Therapy & Infectious Diseases 3:20. AmsterdamGoogle Scholar
  80. 80.
    Hulskotte EGJ,Gupta G, Xuan F, et al. (2013) Lack of Clinically Relevant Drug Interactions Between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Telaprevir (Abstract 1576) 53th International Congress on Antimicrobial Agents and Chemotherapy, Denver. Accessed 10-13 Sept 2013Google Scholar
  81. 81.
    Johnson M, Borland J, Chen S et al (2013) The effect of Boceprevir and Telaprevir on dolutegravir pharmacokinetics, in healthy adult subjects (abstract O_16). In: 14th International Workshop onClinical Pharmacology of HIV Therapy. Reviews in Antiviral Therapy & Infectious Diseases 3:19. AmsterdamGoogle Scholar
  82. 82.
    Kakuda TN, Leopold L, Nijs S et al (2012) Pharmacokinetic interaction between etravirine or rilpivirine and Telaprevir: a randomised, two-way crossover trial (abstract O_18). In: 13th International Workshop on Clinical Pharmacology of HIV Therapy. Reviews in Antiviral Therapy & Infectious Diseases 2013. 3:21. BarcelonaGoogle Scholar
  83. 83.
    Garg V, Kauffman RS, Beaumont M, van Heeswijk RPG (2012) Telaprevir: pharmacokinetics and drug interactions. Antivir Ther (Lond) 17(7):1211–1221CrossRefGoogle Scholar
  84. 84.
    Adiwijaya B, Chandorkar G, Van Heeswijk RPG et al (2011) Effect of mild and moderate hepatic impairment on Telaprevir pharmacokinetics (abstract PK_1). In: 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy. Reviews in Antiviral Therapy & Infectious Diseases 2011. 6:3. CambridgeGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Sarah Talavera Pons
    • 1
    • 5
  • Geraldine Lamblin
    • 2
  • Anne Boyer
    • 1
  • Valérie Sautou
    • 1
    • 4
  • Armand Abergel
    • 2
    • 3
  1. 1.Department of PharmacyClermont-Ferrand University HospitalClermont-FerrandFrance
  2. 2.Department of Hepato-GastroenterologyEstaingClermont-FerrandFrance
  3. 3.Unité Mixte de Recherche Université d’Auvergne, CNRS 6284University of Clermont-FerrandClermont-FerrandFrance
  4. 4.EA 4676 C-BiosenssUniversité d’AuvergneClermont-Ferrand CedexFrance
  5. 5.Service PharmacieCHU EstaingClermont-FerrandFrance

Personalised recommendations